Puretech Health (LON:PRTC)‘s stock had its “buy” rating reaffirmed by analysts at Numis Securities in a research report issued to clients and investors on Tuesday, February 20th. They presently have a GBX 259 ($3.58) price objective on the stock. Numis Securities’ price target would indicate a potential upside of 59.88% from the stock’s previous close.
Several other equities analysts have also recently issued reports on the stock. Peel Hunt reaffirmed a “buy” rating and issued a GBX 302 ($4.17) price objective on shares of Puretech Health in a research note on Tuesday, December 19th. Liberum Capital reaffirmed a “buy” rating and issued a GBX 248 ($3.43) price objective on shares of Puretech Health in a research note on Thursday, November 30th. N+1 Singer reaffirmed a “buy” rating on shares of Puretech Health in a research note on Thursday, November 30th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Puretech Health in a research note on Friday, November 17th. Five analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of GBX 260.20 ($3.59).
Shares of Puretech Health (LON:PRTC) traded up GBX 4 ($0.06) on Tuesday, hitting GBX 162 ($2.24). 50,255 shares of the stock traded hands, compared to its average volume of 66,914. The firm has a market cap of $383.14 and a PE ratio of -852.63. Puretech Health has a 12 month low of GBX 110 ($1.52) and a 12 month high of GBX 183.50 ($2.54).
In other news, insider Robert Langer bought 4,300 shares of the company’s stock in a transaction dated Tuesday, March 13th. The shares were acquired at an average cost of GBX 162 ($2.24) per share, with a total value of £6,966 ($9,624.21).
About Puretech Health
PureTech Health plc is a cross-disciplinary healthcare company. The Company operates through two segments: growth stage businesses and project phase businesses. Businesses in the growth stage businesses segment are those whose activities focus on developing products to solve healthcare problems in varied markets.
Receive News & Ratings for Puretech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puretech Health and related companies with MarketBeat.com's FREE daily email newsletter.